Grace Therapeutics, Inc. (GRCE): Results of Operations and Financial Condition
Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20076145_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Pr
Near-term trading hinges on FDA resubmission path clarity after the CRL and the company’s ability to address CMC/cGMP and non-clinical items without clinical deficiencies.
Grace reports FY2026 results and discloses an April 2026 FDA CRL for its GTx-104 NDA, citing CMC/non-clinical and cGMP issues plus a planned Type A meeting.
Likely two-way volatility: positive if FDA meeting minutes/feedback suggest a straightforward resubmission; negative if CMC/cGMP or non-clinical remediation appears more complex than expected.
Background
Grace Therapeutics is a late-stage biopharma developing GTx-104 (injectable nimodipine) for aSAH; it received an FDA Complete Response Letter in April 2026 for its NDA.
Why it matters
The 8-K provides the newest concrete catalyst: FDA CRL itemization (CMC leachable time points, non-clinical toxicology risk assessments, and cGMP deficiencies with a contract manufacturing organization) and a scheduled Type A meeting to clarify the resubmission path. It also updates FY2026 financials and cash runway, which matter for funding risk during regulatory remediation.
Market relevance
Traders should treat this as a regulatory-path update plus funding/burn context, with the next decision point tied to FDA meeting minutes and the practical resubmission timeline.
Market effects
Highlights ongoing FDA scrutiny of CMC/cGMP and non-clinical packages for late-stage biopharma injectables, reinforcing diligence focus for similar development programs.
Limited direct regional read-through; primarily affects US small/mid-cap biopharma sentiment around FDA resubmission risk.
Modest global relevance given the US FDA-specific CRL and US orphan exclusivity framing.
Alternative perspectives
Even with “no clinical deficiencies,” CMC/cGMP and leachable-data timing can still delay resubmission and increase cost, so the market may discount the optimism until meeting minutes are received.
Cash runway is stated as sufficient for at least 12 months, but the company also flags non-recurring legal/due diligence costs and external consulting/data-management spend tied to the NDA—watch for future burn-rate acceleration around CRL remediation.
Key entities
- companyGrace Therapeutics, Inc.
Nasdaq-listed developer of GTx-104; filed an 8-K with FY2026 results and CRL/resubmission business update.
- productGTx-104
Injectable formulation of nimodipine for IV infusion in aSAH; NDA resubmission is pending after an FDA CRL.
- regulatorFDA
Issued the April 2026 Complete Response Letter and will hold a scheduled Type A meeting to clarify next steps.
